Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
Retrieved on:
Thursday, May 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Complete Response Letter, Rituximab, Graft-versus-host disease, Northwest Biotherapeutics, Febrile neutropenia, CRS, Umbilical cord, Cyclophosphamide, NK, Toxicity, Șaeș, ASCO, Combination therapy, Bone marrow suppression, American Society of Clinical Oncology, Patient, Standard of care, Cytopenia, Annual general meeting, Steroid, Symantec Endpoint Protection, Partial-response maximum-likelihood, Society, Neurotoxicity, ORR, Safety, Vaccine, Pharmaceutical industry, Fever
Artiva Biotherapeutics, Inc. , a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101.
Key Points:
- Artiva Biotherapeutics, Inc. , a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101.
- The presentation will take place on Monday, June 5, during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
- Myelosuppression, consistent with standard lymphodepletion regimens, was the most common Grade ≥ 3 toxicity, but was manageable with standard of care.
- In the combination cohort, only one unrelated Grade 3 SAE of pyrexia was noted. There were no treatment-related AEs leading to discontinuation of AB-101.